Resistance of human renal cell carcinoma (RCC) and melanoma to the apoptosis-inducing effects of IFNs was postulated to result from epigenetic silencing of genes by DNA methylation, a common feature of human cancers. To reverse silencing, 5-AZA-deoxycytidine (5-AZA-dC) or selective depletion of DNA methyltransferase 1 (DNMT1) by phosphorothioate oligonucleotide antisense (DNMT1 AS) were employed in cells resistant (<5% terminal deoxynucleotidyl transferase-mediated nick-end labeling positive) to apoptosis induction by IFN-A2 and IFN-B (ACHN, SK-RC-45, and A375). 5-AZA-dC and DNMT1 AS similarly depleted available DNMT1 protein and, at doses that did not cause apoptosis alone, resulted in apoptotic response to IFNs. The proapoptotic tumor suppressor RASSF1A was reactivated by DNMT1 inhibitors in all three cell lines. This was associated with demethylation of its promoter region. IFNs augmented RASSF1A protein expression after reactivation by DNMT1 inhibition. In IFN-sensitive WM9 melanoma cells, expression of RASSF1A was constitutive but also augmented by IFNs. RASSF1A small interfering RNA reduced IFN-induced apoptosis in WM9 cells and in DNMT1-depleted ACHN cells. Conversely, lentiviral expression of RASSF1A but not transduction with empty virus enabled IFN-induced apoptosis. IFN induced tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL-neutralizing antibody inhibited apoptotic response to IFN in RASSF1A-expressing ACHN cells. Accordingly, RASSF1A markedly sensitized to recombinant TRAIL. Normal kidney epithelial cells, although expressing RASSF1A, did not undergo apoptosis in response to IFN or TRAIL but had >400-fold higher TRAIL decoy receptor 1 expression than transduced ACHN cells (real-time reverse transcription-PCR). Results identified RASSF1A as regulated by IFNs and participating in IFN-induced apoptosis at least in part by sensitization to TRAIL. (Cancer Res 2006; 66(5): 2785-93) 
Introduction
As a result of direct effects on cell function, IFNs play a critical role in host response to virus infection and cancer through influences on viral replication and on tumor cell survival, differentiation, and motility (1) (2) (3) . Activation of a signal cascade by IFNs culminates in induction of several hundred IFN-stimulated genes (ISG) that produce the cellular effects (4, 5) . Resistance of cells to IFNs has been related not only to defects in specific components of the signaling cascade but also to homeostatic mechanisms that modulate receptor activation and transcriptional response (1) (2) (3) . Epigenetic silencing of genes critical for effects of IFNs is a mechanism that also could influence cellular response and resistance. Although direct consequences for cell function have been little evaluated, gene profiling and expression studies indeed have identified genes involved in IFN pathways that are epigenetically silenced by hypermethylation of their 5Vregulatory regions (6) (7) (8) (9) .
Maintenance of DNA methylation in the promoter region of genes can result in heritable silencing of expression just as do mutational deletions (10) . The degree of enzymatic redundancy in this process with the maintenance DNA methyltransferase 1 (DNMT1) and de novo DNMTs, such as DNMT 3b (11) , is still an unresolved issue. However, at least in a colon (12) , a breast, and a lung cancer (13) cell line, inhibition of DNMT1 by oligonucleotide antisense or small interfering RNA (siRNA) was sufficient for reexpression of silenced genes. Epigenetic inactivation of genes that control DNA stability, cell proliferation, and apoptosis is integral to the neoplastic process (10) . IFNs have increased expression of tumor suppressor genes, such as p53 (14) , that are frequently affected by mutational loss of function in cancer, and other ISGs that can be silenced by DNA methylation, such as XAF1, may have tumor suppressor gene function (5, 6) . Nephrectomy specimens and resections of primary melanomas revealed a high frequency of silencing by promoter hypermethylation of the tumor suppressor gene RASSF1A in papillary (up to 100% of patients; ref. 15) and clear cell renal cell carcinoma (RCC; up to 90%; refs. 15, 16) and in melanomas (55%; ref. 17) . RASSF1A plays a role in mitosis control; it can furthermore interact with the proapoptotic kinase MST1 and the scaffolding protein CNK1 to induce apoptosis and has facilitated death receptor-induced Bax conformational change and apoptosis by relieving inhibition of MAP-1 (18) (19) (20) (21) (22) (23) (24) . Apoptosis has been increasingly recognized as one of the mechanisms that may play a role in antitumor effects of IFNs (25) . We postulated that epigenetic silencing of RASSF1A might confer resistance to apoptosis induction by IFNs in RCC and melanoma. Thus, the effects of the wellestablished potent DNA demethylating agent 5-AZA-deoxycytidine (5-AZA-dC) were assessed in RCC and melanoma cell lines that were resistant to apoptosis induction by IFNs and did not express RASSF1A. The specific role of DNMT1 for gene silencing and IFN resistance was evaluated using a selective phosphorothioate antisense oligonucleotide inhibitor (DNMT1 AS) in the more readily transfectable RCC cells.
Materials and Methods
Cell lines/IFNs/tumor necrosis factor-related apoptosis-inducing ligand reagents. ACHN, A375, HeLa (American Type Culture Collection, Manassas, VA), SK-RC-45 (Memorial Sloan Kettering, NY), WM9 (Wistar Institute, PA), and normal kidney epithelial cells [isolated after review by a staff pathologist from abundant tissue of nephrectomies done at the Cleveland Clinic Foundation (CCF), OH and used in 2nd or 3rd passage, kindly provided by Dr. J. Finke, CCF] were cultured at 37jC in 5% CO 2 using MEM (or DMEM; Life Technologies/Invitrogen, Carlsbad, CA) with 0.1 mmol/L nonessential amino acids, 1.0 mmol/L pyruvate, 10% fetal bovine serum, penicillin G (50 units/mL), and streptomycin (50 Ag/mL) and were regularly confirmed Mycoplasma free. NHEM normal human neonatal melanocytes (Cambrex, Baltimore, MD) were cultured under the same incubator conditions but in melanocyte media (Cambrex) according to the supplier's recommendations. Recombinant IFNa2b (Schering-Plough, Kenilworth, NJ) and IFN-h1a (Serono, Rockland, MA) had specific activities of 2 Â 10 8 units/mg protein. Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was obtained from PeproTech (Rocky Hill, NJ), rabbit polyclonal TRAIL neutralizing antibody and control rabbit immunoglobulin were from ProSci (Poway, CA).
DNMT1 inhibition and siRNA transfections. To down-regulate DNMT1, cells were transfected with MG98 (MethylGene, Montreal, Quebec, Canada), a second-generation 4 Â 4 2V O-methyl (bold) phosphorothioate oligonucleotide antisense against the 3V untranslated region of DNMT1 mRNA (5V -TTCATGTCAGCCAAGGCCAC-3V ) or mismatch control oligonucleotide of similar sequence (5V -TTAATGTAACCTAAGGTCAA -3V ) starting 1 day after plating at cell concentrations that allowed at least doubling of number in 48 hours and optimal transfection efficiency (5,000 and 15,000 cells/cm 2 for SK-RC-45 and ACHN cells, respectively). Transfections were with 6.25 Ag/mL Lipofectin in Opti-MEM (Life Technologies/Invitrogen) over 4 hours. Before and after transfections, cells were washed with PBS; every second day, cells were replated 4 hours after the end of the preceding transfection. 5-AZA-dC (Sigma-Aldrich, St Louis, MO) was freshly thawed solution and diluted into media. Cells were replated 4 hours after 5-AZA-dC every 2 days into complete media not containing 5-AZA-dC. siRNA transfections were done like DNMT1 AS transfections but only once and with preincubation of siRNA (0.3 volume of the final amount of Lipofectin) to allow for formation of complexes. siRNAs were obtained from Dharmacon (Lafayette, CO). RASSF1A siRNA sequence was as published (23): 5V -GACCUCUGUGGCGACUUCA-3V(sense); control siRNA sequence was 5V -CACGUCUCUCCCGACUAGA-3V(sense).
Western blotting. Protein (20-40 Ag) from whole-cell lysates were probed for DNMT1 by polyclonal antibodies (MethylGene); signal transducers and activators of transcription 1 (STAT1), STAT2, STAT3 by monoclonal antibody (mAb; BD Transduction Laboratories, San Jose, CA); caspase-3 by pAB (Biomol International L.P., Plymouth Meeting, PA); RASSF1A by mAb (eBioscience, San Diego, CA); MST1 by pAB (Cell Signaling, Beverly, MA); and actin by mAb (Sigma-Aldrich) after separation in 8% to 14% SDS-polyacrylamide gels and transfer to polyvinylidene difluoride (PVDF) membranes. For detection of bound primary antibody, PVDF membranes were incubated with horseradish-tagged goat anti-mouse or goat anti-rabbit antibody (Bio-Rad, Hercules, CA) followed after washing with TBST, by staining with enhanced chemiluminescence solution (Amersham, Piscataway, NJ). To compare relative RASSF1A expression, densitometry was done using Bio-Rad Chemi Doc XRS and Quantity One-4.5.2 1D analysis software (Bio-Rad). All signals were normalized to corresponding actin signals of stripped membranes.
Apoptosis assays. For terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assay, cells were harvested and processed according to the manufacturer's instructions (BD PharMingen, San Diego, CA). Apoptosis was confirmed with an assay for the activity of caspase-3 (BD Clontech, Palo Alto, CA), done according to the manufacturer's instructions, or caspase-3 cleavage detection by immunoblot (polyclonal caspase-3 antibody from Biomol International) 48 hours after IFNs. All results were confirmed with at least one additional analysis.
RNA isolation and cDNA synthesis for PCR. RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) and cDNA prepared with a superscript III first-strand synthesis kit, including a final Rnase H digestion step (Invitrogen), according to the manufacturer. For real-time reverse transcription-PCR (RT-PCR), custom Taqman expression primers (Applied Biosystems, Foster City, CA) were used according to the manufacturer instructions using ABI PRISM Sequence Detection Instrument 7700 (Applied Biosystems).
Bisulfite modification and methylation-specific PCR. Genomic DNA (1 Ag), harvested with a blood DNA mini kit (Qiagen, Valencia, CA), for bisulfite modification with the CpGenome kit (Chemicon International, Temecula, CA) according to the manufacturer's instructions; 4 AL of bisulfite modified DNA was used per 25 AL methylation-specific PCR (MSP) reaction. Primers for RASSF1A MSP were as published (26) . For PCR, methylated (M) primer pairs were denatured at 95jC for 5 minutes followed by 35 cycles with a 1-minute denaturation step, 30 seconds of annealing at 60jC, and 30 seconds of extension at 72jC. Final extension after 35 cycles was at 72jC for 4 minutes. For sequences specific for unmethylated (U) DNA, annealing was at 55jC.
RASSF1A reactivation and sequencing. RT-PCR was with primers that amplified RASSF1 variants regulated by a promoter hypermethylated in cancer (19) . Primers were 5V -AGCGTGCCAACGCGCTGCGCAT-3V (sense) and 5V -CAGGCTCGTCCACGTTCGTGTC-3V(antisense). Settings were 95jC for 4 minutes (95jC for 1 minute, 52jC for 30 seconds, 72jC for 30 seconds for 30 to 35 cycles) and 72jC for 4 minutes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified with the settings 95jC for 4 minutes (95jC for 45 seconds, 55jC for 30 seconds, 72jC for 50 seconds for 15 to 25 cycles) and 72jC for 4 minutes. GAPDH primers were 5V -CAGACCTACTCAGGGATTC-3V(sense) and 5V -GAGCCAGACGCTGCTTTGT-3V(antisense). For sequencing of full-length RASSF1 cDNA in DNMT1 AStreated ACHN cells, RT-PCR with primers 5V -CGCCCAGTCTGGATCCTG-3V (sense) and 5V -CTCAATGCCTGCCTTATTCTG-3V(antisense) was done using proofreading platinum Pfx polymerase (Invitrogen): denaturation at 95jC for 4 minutes followed by 30 cycles at 95jC for 45 seconds, annealing at 58jC for 30 seconds, and extension at 68jC for 3 minutes followed by final extension at 68jC for 8 minutes. Products were cloned into Zero Blunt cloning vector and then into pcDNA4 for expansion. Sequencing of four independent bacterial clones all identified RASSF1A (NM_007182) with a single nucleotide polymorphism at nucleotide 528 (T instead of G), leading to a conservative change at amino acid position 133 (serine for alanine). Before cloning into lentivirus, all CpG sites 5Vof the translation start site were excluded by amplification with primers 5V -GGATCCACCATGTCGGGG-3V (sense) and 5V -CTTCCGTCTGTCGTCCGCTATAG-3V (antisense) using proofreading platinum Pfx polymerase (Invitrogen): denaturation at 94jC for 4 minutes followed by 25 cycles of denaturation at 94jC for 30 seconds, annealing at 63jC for 30 seconds, and extension at 68jC for 2 minutes followed by final extension at 68jC for 8 minutes.
Construction of RASSF1A lentivirus and transduction. RASSF1A cDNA from DNMT1 AS-treated cells was used for overexpression. The BamHI and EcoRV fragment of the RASSF1A open reading frame was subcloned into the corresponding sites of a modified self-inactivating lentiviral vector LRV (6.9 kb), with a blasticidin resistance marker (confirmed by sequencing) and was then transfected into 293T cells along with the packaging plasmids possessing the gag-pol, rrev, and vesicular stomatitis virus glycoprotein G for production and propagation of transducable Lenti-RASSF1A virus. Transductions into ACHN cells were two to three times at 20 to 30 multiplicities of infection of Lenti-RASSF1A virus (10 Ag/mL polybrene); 3 days later, blasticidin (10 Ag/mL) was added. Colonies were pooled, expanded, and RASSF1A verified by Western blot using RASSF1A mAb (eBioscience). Subsequently, the RASSF1A-expressing cells were selected in medium containing blasticidin, and sequence confirmation was repeated.
whether a potent DNMT1 inhibitor would influence apoptosis induction by IFNs, cells were treated with 5-AZA-dC for 2 to 6 days. After incorporation into DNA, 5-AZA-dC covalently binds DNMT1, leading to reduction of available DNMT1 protein in cells and whole-cell lysates (10, 12) . Although 5-AZA-dC alone resulted in some apoptosis, apoptosis was markedly increased after the addition of IFN-a2 and even more so after IFN-h ( Fig. 1A-C) .
In contrast, no augmentation of apoptosis by IFN-h was observed in normal human neonatal melanocytes (NHEM) or normal kidney epithelial cells (NKE) after pretreatment with 5-AZA-dC (D). In nonmalignant cells 5-AZA-dC toxicity correlated with doubling times, which were f4 days for NHEM, 3 days for NKE 01, and 2 days for NKE 02 (data not shown). To confirm reduction in DNMT1, cell lysates were subjected to Western blot analysis. 5-AZA-dC markedly decreased DNMT1 protein (immunoblots in Fig. 1A-D) .
To determine whether DNMT1 depletion was sufficient for overcoming resistance to IFN-induced apoptosis, ACHN cells were transfected daily with 40 nmol/L DNMT1 AS. Nearly complete suppression of DNMT1 protein was achieved by day 4 in ACHN cells ( Fig. 2A) . In contrast, DNMT1 AS did not influence expression of STAT1, STAT2, or STAT3 ( Fig. 2A ). This latter result was further confirmed by RT-PCR for STAT1 (data not shown) and cRNA array (data not shown).
In the absence of DNMT1, cell divisions should yield daughter cells with demethylated genes; therefore, transfections were continued for an additional 2 to 4 days before apoptosis assessment. The duration of DNMT1 depletion correlated with sensitization of ACHN cells to even low doses (50 units/mL) of IFNa2 or IFN-h ( Fig. 2A) . Mismatch control oligonucleotide did not sensitize to IFN-induced programmed cell death ( Fig. 2A) . Apoptosis was confirmed by immunoblotting for detection of cleaved (activated) caspase-3 ( Fig. 2A) and by caspase-3 activity assays (data not shown).
Similarly in SK-RC-45 cells, after 4 or 6 days of DNMT1 AS treatment, complete suppression of DNMT protein expression was achieved with no effect of the mismatch (Fig. 2B) . Treatment with 500 units/mL IFN-a2 or IFN-h after DNMT1 depletion for 6 days increased the apoptotic fraction from 5.4 F 4.5% to 23.4 F 12% and 45 F 1% (mean F SD), respectively, whereas after mismatch IFNs caused apoptosis in <10% of cells (Fig. 2B) . Apoptosis was also confirmed by caspase-3 activity assays (data not shown).
In A375 melanoma cells, only minimal reduction of DNMT1 protein resulted from nontoxic concentrations of DNMT1 AS (data not shown), whereas treatment with 200 nmol/L 5-AZA-dC over 4 days reduced available DNMT1 protein and increased frequency of apoptotic cells from 1.5 F 1.1% in controls to 22.9 F 3% (mean F SD) after 100 units/mL IFN-h, while alone causing little apoptosis (4.7 F 1.85% apoptotic cells; Fig. 1C) .
Because the lowest nontoxic schedule of 5-AZA-dC resulted in less IFN-induced apoptosis than the DNMT1 AS in the RCC cell lines, DNMT1 AS was mostly used for subsequent experiments with these cells, and subsequent experiments in A375 used 5-AZA-dC.
Effects of DNMT1 depletion on expression and promoter region of RASSF1A. To determine whether RASSF1A might be involved in induction of apoptosis by IFNs after DNMT1 inhibition, its expression was assessed in the IFN-resistant cell lines after both DNMT1 AS and 5-AZA-dC. Duration of DNMT1 depletion correlated with reexpression of RASSF1A mRNA, as shown in ACHN cells (Fig. 3A) . DNMT1 AS (40 nmol/L over 6 days) or 5-AZAdC (200 nmol/L over 4 days) also reactivated RASSF1A expression in SK-RC-45 cells (Fig. 3A) . Although it was not possible to deplete DNMT1 by AS at doses allowing for continuing cell divisions in A375 cells 5-AZA-dC led to reactivation of RASSF1A expression (Fig. 3A) . To confirm that RASSF1A expression was related to methylation status of its promoter region, MSP was undertaken. Reactivation of RASSF1A was associated with demethylation of a promoter CpG island in ACHN cells (Fig. 3B) .
Effect of DNMT1 depletion and IFNs on RASSF1A protein expression. To determine whether reactivation of RASSF1A transcription was followed by translation into protein and whether this was influenced by IFN treatment, immunoblots were done. Transfection with DNMT1 AS reactivated RASSF1A protein expression, an effect that was further augmented by IFNs (Fig. 3C) . Similar results occurred in A375 cells treated with 5-AZA-dC; after pretreatment with 5-AZA-dC, IFN-h induced RASSF1A protein (Fig. 3C) . Hypothesizing that RASSF1A might be involved in IFN-induced apoptosis, its expression was determined in a melanoma cell line (WM9) known to undergo programmed cell death upon treatment with IFN-h (27) . In contrast to ACHN cells, RASSF1A mRNA and protein were constitutively expressed in WM9 cells (Fig. 3A and C) . Addition of IFN-h to WM-9 cells further augmented RASSF1A protein expression (Fig. 3C) . Thus, unless RASSF1A was silenced, IFNs could increase RASSF1A expression.
To further assess interactions between IFNs and RASSF1A, activation of MST1, an apoptotic partner molecule of RASSF1A, was also assessed. MST1 was cleaved (activated; ref. 28) after IFNs in DNMT1 AS but not control oligonucleotide (mismatch)-pretreated ACHN cells (Fig. 3C) . Thus, not only did IFNs augment RASSF1A expression, but the increased protein was associated with enhanced proapoptotic protein activation.
Effect of suppression of RASSF1A by siRNA on IFN-induced apoptosis. To determine whether RASSF1A played a role in apoptosis induction by IFNs, ACHN cells depleted of DNMT1 by AS were transfected with RASSF1A siRNA followed by IFN treatment. Inhibition of RASSF1A by siRNA decreased IFN-induced apoptosis in DNMT1 AS-pretreated cells from 63.9 F 9.19% in control siRNA treated cells to 35 F 4.1% (mean F SD), as determined by frequency of TUNEL-positive cells (Fig. 4A) . Parallel assessment of RASSF1A protein expression by densitometry of Western blots identified 67% reduction in DNMT1 AS-treated cells and 61% reduction in DNMT1 AS-and IFN-h-treated cells by specific compared with control siRNA (Fig. 4A) . Absence of IFN induction by the control siRNA was assessed by real-time RT-PCR for the ISGs XAF1, IRF1, and USP18. None of these genes were up-regulated compared with treatment with Lipofectin transfection reagent alone (0.6-, 1.1-, and 1.0-fold induction, respectively, for each gene).
To further confirm the importance of RASSF1A for IFN-induced apoptosis, WM9 cells, sensitive to apoptosis induction by IFNs alone, were treated with IFN after depletion of RASSF1A by siRNA. Similar reduction of IFN-induced apoptosis by RASSF1A siRNA occurred in WM9 melanoma cells ( from 60.45 F 3.18% in control siRNA-treated cells to 39.2 F 3.11%; Fig. 4B ). RASSF1A protein was reduced by 65% at baseline and 57% in IFN-treated cells by specific compared with control siRNA, as determined by densitometry (Fig. 4B) . Thus, a limited suppression of RASSF1A partially inhibited apoptosis induced by IFN-h.
Effect of lentiviral expression of RASSF1A on apoptosis induction by IFNs. To further confirm the role of RASSF1A in overcoming resistance to IFN-induced apoptosis, independent of any other genes reactivated by DNMT1 depletion, forced expression of RASSF1A using a lentiviral construct (Fig. 5A ) was undertaken. After transduction, the population of transduced cells was kept in selective antibiotic for 14 days before RASSF1A protein expression and sensitivity to IFN-induced apoptosis were assessed. Of RASSF1A-transduced cells, 16.83 F 0.98% underwent apoptosis in response to 50 units/mL IFN-h compared with 3.77 F 1.67% (mean F SD) of empty virus-transfected cells (Fig. 5B) . Subcloning of stably transduced cells showed that clones that expressed RASSF1A at levels comparable with the ones achieved by DNMT1 AS treatment (78%, 234%, and 134% relative RASSF1A expression compared with DNMT1 AS by densitometry in clones 1.3, 1.7, and 1.8, respectively; Fig. 5B ) underwent apoptosis in response to 50 units/mL IFN-h (20-40% apoptotic cells; Fig. 5B ). Thus, RASSF1A alone could overcome resistance to IFN-induced apoptosis.
Effect of lentiviral expression of RASSF1A on sensitivity to TRAIL-induced apoptosis. In WM9 cells, Apo2L/TRAIL was known to be induced by IFN-h and to mediate IFN-induced apoptosis (27) , which could be reduced by RASSF1A siRNA (Fig. 4B) . Because a recent report suggests that RASSF1A was required for death receptor-induced Bax conformational change and apoptosis (18) , we hypothesized that RASSF1A may overcome resistance to IFN-induced apoptosis by sensitization to Apo2L/ TRAIL. As determined by real-time RT-PCR, IFN-h (50 units/mL over 16 hours) induced Apo2L/TRAIL in ACHN cells (between 20 and 25 fold). Cotreatment with TRAIL-neutralizing antibody but not control rabbit immunoglobulin partially inhibited IFN-induced apoptosis in RASSF1A-expressing ACHN cells (Fig. 5C) . Accordingly, sensitivity of ACHN cells to Apo2L/TRAIL-induced apoptosis was markedly increased by forced RASSF1A expression (Fig. 5D) .
NKE cells expressed RASSF1A (Fig. 3B ) but even after 5-AZA-dC treatment remained resistant to IFN and Apo2L/TRAIL-induced apoptosis (Fig. 1D and Fig. 5D ). Real-time RT-PCR identified >400-fold higher TRAIL decoy receptor 1 (TRAIL DcR1) expression in NKE compared with transduced ACHN cells, whereas TRAIL receptor 1 and 2 (TRAIL R1 and R2) expression was similar. 5-AZA-dC did not markedly alter the relative expression of proapoptotic (TRAIL R1and R2) to cell-protective (TRAIL DcR1 and DcR2) TRAIL receptors but modestly increased them all (Table 1 ). This suggested that RASSF1A sensitized to IFN-induced apoptosis at least in part by sensitization to Apo2L/TRAIL, and that strong expression of TRAIL DcR1 might protect certain RASSF1A expressing nonmalignant cells from apoptosis induction by IFN or Apo2L/TRAIL.
Discussion
Maintenance of DNA methylation in the promoter region of genes can lead to heritable epigenetic silencing of expression with consequences similar to mutational deletions (10) . Antitumor activity of IFNs, commonly used in the treatment of metastatic RCC and melanoma, depends on induction of gene expression in cancer cells, immune cells, and cells regulating angiogenesis (1) .
Hypothesizing that unsatisfactory response rates of melanoma and RCC to IFN (about 15%) are in part due to epigenetic silencing of genes, the role of a tumor suppressor gene that is frequently silenced in both malignancies (15-17) was examined in vitro. Treatment of three cell lines (two renal and one melanoma) that were resistant to apoptosis induction by high doses of IFN-a2 and IFN-h (500 units/mL) with the DNAdemethylating nucleoside analogue 5-AZA-dC overcame resistance to IFN-induced apoptosis (Fig. 1A-C) and reactivated expression of RASSF1A (Fig. 3) .
5-AZA-dC is a nucleoside analogue that after incorporation into DNA inhibits DNMT1 by covalent binding (10) . DNMT1 is thus trapped and not available at the DNA replication fork to copy methylation patterns from mother to daughter strand, resulting in demethylation upon cell division. The covalent binding of the f190-kDa DNMT1 protein to DNA, however, also results in DNA damage; thus, 5-AZA-dC may have effects in cells, independent of its DNA-demethylating activity (29, 30) . Sensitization to IFNinduced apoptosis was observed at 5-AZA-dC doses that did not result in apoptosis alone (Fig. 1 ) associated with reactivation of RASSF1A mRNA expression (Fig. 3A) . More importantly, specific inhibition of DNMT1 AS similarly reactivated RASSF1A and overcame resistance to apoptosis induction by IFNs (Figs. 2-3) . Compared with mismatch control oligonucleotide, transfection reagent alone, and media alone, DNMT1 AS did not induce ISGs ( Fig. 2A ; data not shown), suggesting that its effect on IFN resistance was due to DNMT1 depletion ( Fig. 2A) and associated DNA demethylation (Fig. 3B) . These results furthermore support that at least in RCC cells, which were more amenable to downregulation of DNMT1 by AS than studied melanoma cells, DNMT1 was critical for silencing of genes.
Containing a diacylglycerol and a rasGTP binding domain but no catalytic activity, RASSF1A has influenced function of binding partners, including the E1A-regulated transcription factor p120 (E4F; ref. 31), the proapoptotic kinase MST1 (20, 22, 32) , the scaffold protein CNK1 (22) , and cdc20, an activator of anaphase promoting complex (24) . Interaction of RASSF1A with cdc20 regulated mitotic progression (21, 24) and apoptosis resulted when RASSF1A was coexpressed with the scaffold protein CNK1 (22) . RASSF1A directed MST1 to the cell membrane, where MST1 can be activated influencing apoptosis (20, 22) . Because it was activated by IFNs after RASSF1A reexpression (Fig. 3C ), MST1 may be contributory to the apoptotic effects of IFNs. Interestingly, IFNs also increased protein expression of RASSF1A after DNMT1 depletion and in cells with baseline expression (Fig. 3C) . The exact mechanism of RASSF1A protein regulation by IFNs will need to be studied in future experiments, but real-time RT-PCR results suggest post-transcriptional events (data not shown).
In DNMT1-depleted ACHN cells, selective suppression of RASSF1A by siRNA reduced apoptosis in response to IFN from 63.9 F 9.19% to 35 F 4.1% (mean F SD; Fig. 4A ). Rationalizing that cells sensitive to apoptosis induction by IFNs might express RASSF1A, WM9 cells (27) were studied. Without treatment, RASSF1A was expressed, IFN increased expression (Fig. 3A and  C) , and RASSF1A siRNA reduced IFN-h-induced apoptosis from 60.45 F 3.18% to 39.2 F 3.11%, accompanied by reduction of RASSF1A protein expression (Fig. 4B) . Conversely, in ACHN cells, lentiviral expression of RASSF1A protein to levels comparable with the one achieved by DNA demethylation overcame resistance to IFN-induced apoptosis (Fig. 5) .
Recent evidence has suggested requirement of RASSF1A for death receptor-induced Bax conformational change and apoptosis. RASSF1A enabled Bax apoptotic signaling by relieving an inactivating intramolecular conformation of a necessary partner molecule of Bax, BH3-like protein modulator of apoptosis-1 (MAP-1; ref. 18 ). Apo2L/TRAIL was induced by IFN-h (50 units/mL) in ACHN cells, 20-to 25-fold as determined by real-time RT-PCR (data not shown), and TRAIL-neutralizing antibody inhibited IFN-induced apoptosis of RASSF1A-expressing cells (Fig. 5C) . Accordingly, RASSF1A markedly sensitized ACHN cells to Apo2L/ TRAIL-induced cell death (Fig. 5D) .
On the other hand, NKE cells did not undergo programmed cell death in response to IFN or TRAIL despite expression of RASSF1A and no synergism of 5-AZA-dC with either drug was observed (Fig. 1D, Fig. 3A, and Fig. 4D ). Real-time RT-PCR before and after 4 days of 5-AZA-dC treatment revealed >400-fold higher TRAIL DcR1 expression in NKE compared with ACHN cells (Table 1) . TRAIL decoy receptors bind Apo2L/TRAIL without transmission of apoptotic signals into the cell (33) . Thus, RASSF1A overcame resistance to IFN-induced apoptosis at least in part by sensitization to Apo2L/TRAIL, and strong TRAIL decoy receptor expression might protect certain nonmalignant RASSF1A-expressing cells from cell death induction by IFN or Apo2L/TRAIL.
Promoter hypermethylation of ISGs, including DAPK (mainly lymphoid malignancies), XAF1 (gastric), and IRF7 ( fibrosarcoma), as well as of genes essential for IFN apoptotic signaling, like TRAIL R1 and caspase-8 (lung), have been identified in cell lines and/or biopsy specimens (6-9). Although not described as frequently hypermethylated in renal cancer, reactivation of such genes could have contributed to sensitization of ACHN cells to IFN-induced apoptosis after DNMT1 depletion. However, except for one ISG of unknown function, IFI27, no other ISGs or genes known to be essential for IFN apoptotic signaling (25) were increased in expression by DNMT1 AS treatment in ACHN cells, as determined by U133A Affymetrix cRNA array (data not shown). Although TRAIL R1 and TRAIL R2 were not represented on the array, quantitative RT-PCR did not identify evidence for their reactivation by DNMT1 AS (data not shown). However, among the 137 genes increased at least 2-fold in DNMT1 AS over mismatch treated cells, eight had roles in apoptosis and also may have contributed to overcoming resistance to IFN-induced programmed cell death by influencing apoptotic pathways (small GTPase ARHGDIB), inhibition of NF-nB (NFKBIA, IER3, and C8FW), or other mechanisms (PHLDA1, NAC, STK17A, and ASC; data not shown). IFN-a2 has increased survival of patients with metastatic RCC in randomized trials, albeit only for several weeks to months (1, 34) . Prolongation of disease-free and possibly overall survival has resulted when IFN-a2 has been administered to melanoma patients for high-risk primary disease (1) . Resistance of RCC and melanoma cells to the apoptosis-inducing effects of IFN-a2 and IFN-h was overcome by inhibition of DNMT1 (Figs. 1 and 2) . This was at least in part due to reactivation of the tumor suppressor gene RASSF1A (Figs. 4 and 5 ) that is frequently silenced by DNA methylation in RCC and melanoma (15) (16) (17) and as shown herein up-regulated in expression by IFNs (Fig. 3C) . By targeting DNMT1 in RCC and melanoma, clinical antitumor effects of IFNs may be augmented through reactivation of silenced RASSF1A and possibly by reactivation of other heterogeneously silenced genes in IFN pathways.
